The Food and Drug Administration (FDA) has placed a clinical hold on three trials involving the cancer drug Keytruda (pembrolizumab) in patients with the blood cancer multiple myeloma, raising concerns about the number of patients who have died after receiving the drug. The announcement comes just weeks after a review by the Data Monitoring Committee during which more deaths were observed in patients who had been treated with Keytruda, which led to the FDA ordering a hold on new enrollment in two of the three studies. Merck was testing the anti-PD-1 therapy in one trial with Keytruda in combination with Pomalyst ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.